全文获取类型
收费全文 | 521篇 |
免费 | 31篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 9篇 |
妇产科学 | 1篇 |
基础医学 | 30篇 |
口腔科学 | 5篇 |
临床医学 | 19篇 |
内科学 | 113篇 |
皮肤病学 | 1篇 |
神经病学 | 12篇 |
特种医学 | 9篇 |
外科学 | 173篇 |
综合类 | 5篇 |
一般理论 | 1篇 |
预防医学 | 10篇 |
眼科学 | 6篇 |
药学 | 63篇 |
中国医学 | 2篇 |
肿瘤学 | 94篇 |
出版年
2024年 | 1篇 |
2023年 | 6篇 |
2022年 | 9篇 |
2021年 | 39篇 |
2020年 | 22篇 |
2019年 | 16篇 |
2018年 | 24篇 |
2017年 | 18篇 |
2016年 | 16篇 |
2015年 | 15篇 |
2014年 | 36篇 |
2013年 | 48篇 |
2012年 | 56篇 |
2011年 | 44篇 |
2010年 | 26篇 |
2009年 | 14篇 |
2008年 | 33篇 |
2007年 | 20篇 |
2006年 | 24篇 |
2005年 | 11篇 |
2004年 | 8篇 |
2003年 | 13篇 |
2002年 | 6篇 |
2001年 | 3篇 |
2000年 | 5篇 |
1999年 | 7篇 |
1998年 | 7篇 |
1997年 | 3篇 |
1996年 | 3篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 4篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1903年 | 1篇 |
1902年 | 1篇 |
排序方式: 共有553条查询结果,搜索用时 46 毫秒
121.
Tsao CK Small AC Moshier EL Gartrell BA Wisnivesky JP Sonpavde G Godbold JH Palese MA Hall SJ Oh WK Galsky MD 《Clinical genitourinary cancer》2012,10(3):159-163
BackgroundTwo randomized trials published in 2001 established CyNx for patients with metastatic renal carcinoma (mRCC) as a treatment standard in the cytokine era. However, first-line systemic therapy for mRCC changed in 2005 with FDA approval of VEGFR TKIs. We evaluated the patterns of use of CyNx from 2000 to 2008.Materials and MethodsThe National Cancer Database was queried for patients diagnosed with mRCC. Patients who underwent CyNx were identified and were further categorized by pre-VEGFR versus VEGFR TKI era, race, insurance status, and hospital. For these subcategories, prevalence ratios (PRs) were generated using the proportion of patients with mRCC undergoing CyNx versus those not undergoing CyNx.ResultsOf the 47,417 patients (pts) identified with mRCC, the prevalence of cytoreductive nephrectomy increased 3% each year from 2000 to 2005 (P < .0001), then decreased 3% each year from 2005 to 2008 (P = .0048), with a significant difference between the eras (0.97 vs. 1.025; P < .0001). Black and Hispanic pts were less likely than Caucasian pts to undergo CyNx. Pts with Medicaid, Medicare, and no insurance were less likely than pts with private insurance to undergo CyNx. Pts diagnosed at community hospitals were significantly less likely than pts at teaching hospitals to undergo CyNx.ConclusionThe use of CyNx has declined in the VEGFR-TKI era. In addition, racial and socioeconomic disparities exist in the use of CyNx. The results of pending randomized trials evaluating the role of CyNx in the VEGFR-TKI era are awaited to optimize use of this modality and address potential disparities. 相似文献
122.
Sonpavde G Vogelzang NJ Galsky MD Raghavan VA Daniel S 《American journal of clinical oncology》2012,35(2):163-166
Performance status, a measure of physical functioning, can be influenced by several undefined physician and patient-related factors, and is inherently subjective. Although disappointing results in phase 3 trials may reflect a lack of improved outcomes due to biological mechanisms, a confounding effect of imbalances of physical functioning cannot be excluded in the context of modest increments in antitumor activity. Therefore, performance status estimation may complicate drug development, and an objective measure of physical reserve is desirable and may complement or outperform performance status. We explore and discuss attractive candidates for objective measures of physical functioning. 相似文献
123.
Matthew H. Hayn Abid Hussain Ahmed M. Mansour Paul E. Andrews Paul Carpentier Erik Castle Prokar Dasgupta Peter Rimington Raju Thomas Shamim Khan Adam Kibel Hyung Kim Murugesan Manoharan Mani Menon Alex Mottrie David Ornstein James Peabody Raj Pruthi Joan Palou Redorta Lee Richstone Francis Schanne Hans Stricker Peter Wiklund Rameela Chandrasekhar Greg E. Wilding Khurshid A. Guru 《European urology》2010
124.
Derya Tilki Oliver Reich Pierre I. Karakiewicz Giacomo Novara Wassim Kassouf Süleyman Ergün Yves Fradet Vincenzo Ficarra Guru Sonpavde Christian G. Stief Eila Skinner Robert S. Svatek Yair Lotan Arthur I. Sagalowsky Shahrokh F. Shariat 《European urology》2010
Background
The current TNM bladder cancer staging system stratifies bladder muscle invasion into superficial (pT2a) and deep (pT2b). Controversy exists regarding the significance of the extent of muscle invasion on clinical outcome.Objective
Our aim was to compare the cancer-specific outcomes of patients with pT2 urothelial carcinoma of the bladder (UCB) at radical cystectomy (RC) in a large international cohort of patients.Design, setting, and participants
The records of patients treated with RC for UCB at six centers were reviewed. Of the 2605 reviewed patients, 565 (21.7%) had pT2 disease. None of the patients received preoperative systemic chemotherapy or radiotherapy.Measurements
Patients’ characteristics and outcome were evaluated.Results and limitations
The median patient age in the entire group was 66.2 yr. Of the 565 patients with pT2 UCB, 249 patients (44.1%) had substage pT2a; 316 patients (55.9%) had pT2b. One hundred and eleven patients (19.6%) had metastases to regional lymph nodes. Median follow-up was 50.5 mo. Recurrence-free survival (73.2% vs 58.7%) and cancer-specific survival (78.0% vs 65.1%) estimates were significantly better for pT2a patients compared with those with pT2b (p = 0.002 and p = 0.001, respectively). Pathologic T2 substaging was associated with worse recurrence-free and cancer-specific survival after adjusting for the effects of standard pathologic features (p = 0.011 and p = 0.006, respectively). The statistical significance of these associations was reconfirmed in subgroup analysis limited to those patients with pathologically negative lymph nodes.Conclusions
In this large international cohort, pathologic substaging helped to stratify patients with lymph node–negative pT2 UCB into statistically significantly different risk groups. These data support the value of the current American Joint Committee on Cancer TNM staging. 相似文献125.
PurposeSunitinib malate (Pfizer, Inc.) is a multitargeted kinase inhibitor that inhibits vascular endothelial growth factor (VEGF) receptor (R)-1, 2 and 3, platelet-derived growth factor receptors (PDGFR)-α and β, Flt3, RET, and Kit. Angiogenesis and VEGF expression correlate with poor outcomes in human urothelial carcinoma. We designed a preclinical study to examine the efficacy of sunitinib alone and in combination with cisplatin against human urothelial carcinoma.DesignThe in vitro activities of sunitinib and cisplatin alone and in combination were determined against human urothelial carcinoma cell lines, TCC-SUP and 5637. Antitumor activities were also determined in vivo against murine subcutaneous 5637 xenografts. Immunohistochemistry (IHC) was performed to detect VEGFR2 and Kit, and modulation of proliferation, apoptosis, and angiogenesis.ResultsBoth cell lines expressed VEGFR2, but did not express Kit. Sunitinib displayed activity against both cell lines in vitro at low micromolar concentrations, which are not attainable in vivo, and was synergistic with cisplatin. Activity was observed for sunitinib at 20 and 40 mg/kg orally once daily for 4 weeks, which attains low nanomolar concentrations in vivo against murine 5637 xenografts. Sunitinib 20 mg/kg/d in combination with cisplatin 4 mg/kg/wk intraperitoneally induced tumor regression compared to no therapy (P < 0.0001) or cisplatin alone (P = 0.06). Cisplatin, sunitinib, and combination treated tumors displayed significantly reduced ki-67 expression compared with control untreated tumors, and the difference was also statistically significant for the combination compared with cisplatin. Cleaved caspase-3 expression was significantly higher for sunitinib single agent and combination therapy compared with untreated controls, and for combination therapy compared with cisplatin alone. CD31 expression was diminished for both single agents and combination therapy compared with untreated tumors.ConclusionsSunitinib is preclinically active against urothelial carcinoma, and enhances the activity of cisplatin probably by targeting the stroma. 相似文献
126.
Inoperable hepatocellular carcinoma: transarterial 188Re HDD-labeled iodized oil for treatment--prospective multicenter clinical trial 总被引:2,自引:0,他引:2
Kumar A Srivastava DN Chau TT Long HD Bal C Chandra P Chien le T Hoa NV Thulkar S Sharma S Tam le H Xuan TQ Canh NX Pant GS Bandopadhyaya GP 《Radiology》2007,243(2):509-519
PURPOSE: To prospectively evaluate, in a multicenter clinical trial, dosimetry-guided transarterial radionuclide therapy (TART) with rhenium 188 ((188)Re) 4-hexadecyl 1,2,9,9-tetramethyl-4,7-diaza-1,10-decanethiol (HDD)-labeled iodized oil in inoperable hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Ninety-three patients were recruited from 2000 to 2005 for this ethics committee-approved study. Informed written consent was obtained. After complete clinical evaluation (including assessment of liver status, serum alpha-fetoprotein [AFP] level, tumor size, portal vein status, Child-Pugh classification, Okuda staging), radiation absorbed dose (RAD) to various organs, including tumor, was calculated after injecting 185 MBq of (188)Re HDD iodized oil via the hepatic artery. From this value, the maximum tolerable activity of (188)Re, defined as the amount of radioactivity delivering no more than 12 Gy of RAD to lungs, 30 Gy to normal liver, or 1.5 Gy to bone marrow, was calculated and injected. RESULTS: Mean patient age was 53 years (80 men and 13 women). Sixty-eight percent of patients had serologic evidence of hepatitis B and/or C; 40% had clinicoradiologic evidence of cirrhosis. Mean tumor diameter was 10.3 cm +/- 4.4, with 40% of patients having more than three lesions; in 50% of patients, tumor was either unilateral, occupying 50% or more of the liver, or bilateral. AFP was elevated in 68% of patients and was elevated to more than 300 ng/mL in 44% of patients. There was portal vein thrombosis in 38% of patients, Child-Pugh status B disease in 37% of patients, and Okuda stage II or III disease in 50% of patients. Mean first administered activity was 5.3 GBq +/- 1.6, which delivered 88 Gy of RAD to the tumor. Treatment was tolerated well. Of 66 patients in whom complete tumor response occurred, five (8%) had complete tumor mass ablation, 17 (26%) had a partial response (>50% tumor reduction), and 23 (35%) had stable disease. Only RAD to the tumors was found to be significantly (P = .001) associated with tumor and/or AFP response. Survival rates at 6, 9, 12, 24, and 36 months among patients with objective tumor response were 100%, 95%, 90%, 58%, and 30%, respectively, with a median survival of 980 days. CONCLUSION: TART appears to be a safe, effective, and promising therapeutic option in patients with inoperable HCC. 相似文献
127.
128.
Matthew D. Galsky Tal Zaks Habib Hassani Linda Vocila Guru Sonpavde Thomas E. Hutson Daniel D. Von Hoff 《Investigational new drugs》2010,28(2):194-198
Purpose: To describe a phase II study design to evaluate the activity of novel anti-cancer agents that focuses on molecular pathogenesis
rather than tumor histology. Methods: We propose an enrichment design that enrolls patients across histologies expressing target X and incorporates randomized
discontinuation of drug Y after an initial treatment period to evaluate for potential cystostatic activity. Results: We are currently evaluating the activity of lapatinib in patients with HER-2 amplified solid tumors using the target-specific, histology-independent, randomized discontinuation design. Patients receive
treatment with lapatinib for an initial 12-week period. After restaging, patients with disease progression are removed from
study, patients achieving an objective response continue treatment, and patients with stable disease are randomized to continue
lapatinib versus initiate treatment with placebo. The primary endpoints are to evaluate the objective response rate during
the initial treatment period and to evaluate the proportion of patients progression-free 12 weeks post-randomization. Conclusion: The target-specific, histology-independent, randomized discontinuation design is an attractive alternative to the traditional
phase II design for the development of “targeted” therapeutics. 相似文献
129.
Matthew D. Galsky MD Ryan Hendricks BS Robert Svatek MD Rick Bangs BA Jean Hoffman‐Censits MD Jessica Clement MD Robert Dreicer MD Elizabeth Guancial MD Noah Hahn MD Seth P. Lerner MD Peter H. O'Donnell MD Diane Zipursky Quale JD Arlene Siefker‐Radtke MD William Shipley MD Guru Sonpavde MD Daniel Vaena MD Jacob Vinson MHA Jonathan Rosenberg MD 《Cancer》2013,119(11):1994-1998
130.